| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Archana Mishra, Rituparna Maiti, Mathan Kumar Ramasubbu, Anand Srinivasa. Evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: A simulation study of clinical data. Psychiatry research. vol 338. 2024-06-02. PMID:38824710. |
evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: a simulation study of clinical data. |
2024-06-02 |
2024-06-05 |
Not clear |
| Archana Mishra, Rituparna Maiti, Mathan Kumar Ramasubbu, Anand Srinivasa. Evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: A simulation study of clinical data. Psychiatry research. vol 338. 2024-06-02. PMID:38824710. |
the aim of the study was to evaluate interaction effect of various augmentation strategies with clozapine in patients with treatment-resistant schizophrenia. |
2024-06-02 |
2024-06-05 |
Not clear |
| Young Joo Park, Sang Min Lee, Won Sub Kan. Empyema in a Patient with Schizophrenia Using Clozapine: A Case Report. Psychiatry and clinical psychopharmacology. vol 32. issue 2. 2024-05-21. PMID:38764862. |
empyema in a patient with schizophrenia using clozapine: a case report. |
2024-05-21 |
2024-05-27 |
Not clear |
| Young Joo Park, Sang Min Lee, Won Sub Kan. Empyema in a Patient with Schizophrenia Using Clozapine: A Case Report. Psychiatry and clinical psychopharmacology. vol 32. issue 2. 2024-05-21. PMID:38764862. |
in this case report, we present 47-year-old woman with schizophrenia who had been using clozapine and did not complain of respiratory symptoms. |
2024-05-21 |
2024-05-27 |
Not clear |
| Miriam Chandad, Rajae Chlihfane, Safae Kodad, Bouchra Oneib, Fatima Elghazouan. Reintroduction of Clozapine following Neuroleptic Malignant Syndrome in a Young Patient with Resistant Schizophrenia. Case reports in psychiatry. vol 2024. 2024-05-21. PMID:38764874. |
reintroduction of clozapine following neuroleptic malignant syndrome in a young patient with resistant schizophrenia. |
2024-05-21 |
2024-05-27 |
Not clear |
| Miriam Chandad, Rajae Chlihfane, Safae Kodad, Bouchra Oneib, Fatima Elghazouan. Reintroduction of Clozapine following Neuroleptic Malignant Syndrome in a Young Patient with Resistant Schizophrenia. Case reports in psychiatry. vol 2024. 2024-05-21. PMID:38764874. |
in the case of resistant schizophrenia treated with clozapine, there are insufficient therapeutic options. |
2024-05-21 |
2024-05-27 |
Not clear |
| Miriam Chandad, Rajae Chlihfane, Safae Kodad, Bouchra Oneib, Fatima Elghazouan. Reintroduction of Clozapine following Neuroleptic Malignant Syndrome in a Young Patient with Resistant Schizophrenia. Case reports in psychiatry. vol 2024. 2024-05-21. PMID:38764874. |
we report the case of a young patient followed up for resistant schizophrenia who developed neuroleptic malignant syndrome after 5 years of therapy with clozapine. |
2024-05-21 |
2024-05-27 |
Not clear |
| Miriam Chandad, Rajae Chlihfane, Safae Kodad, Bouchra Oneib, Fatima Elghazouan. Reintroduction of Clozapine following Neuroleptic Malignant Syndrome in a Young Patient with Resistant Schizophrenia. Case reports in psychiatry. vol 2024. 2024-05-21. PMID:38764874. |
in light of this clinical case and a review of the literature, we report the possibility of reintroducing clozapine following an incidence of malignant syndrome in patients with resistant schizophrenia with respect to certain rules; in particular, a slow increase in dose after a reasonable period of time and close monitoring. |
2024-05-21 |
2024-05-27 |
Not clear |
| Mahmut Selçu. Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report. Psychiatry and clinical psychopharmacology. vol 33. issue 2. 2024-05-21. PMID:38765926. |
safe and effective use of low-dose clozapine for tardive dyskinesia in a patient with schizophrenia and comorbid epilepsy: a case report. |
2024-05-21 |
2024-05-27 |
Not clear |
| Mahmut Selçu. Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report. Psychiatry and clinical psychopharmacology. vol 33. issue 2. 2024-05-21. PMID:38765926. |
atypical antipsychotic clozapine has a special therapeutic impact on tardive dyskinesia and treatment-resistant schizophrenia. |
2024-05-21 |
2024-05-27 |
Not clear |
| Mahmut Selçu. Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report. Psychiatry and clinical psychopharmacology. vol 33. issue 2. 2024-05-21. PMID:38765926. |
for this reason, most clinicians avoid using clozapine in patients with schizophrenia and epilepsy. |
2024-05-21 |
2024-05-27 |
Not clear |
| Delaney R Brainerd, Bruce Alexander, Marshall J Tague, Brian C Lun. Association Between Clozapine Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia. The Journal of clinical psychiatry. vol 85. issue 2. 2024-05-20. PMID:38767931. |
association between clozapine exposure and risk of hematologic malignancies in veterans with schizophrenia. |
2024-05-20 |
2024-05-27 |
Not clear |
| Nadia El Ouni Amami, Husen Ali-Diabacte, Sarra Ateb, Hamadi Ben Rejeb, Avicenne Bellis, Reza Bellis, Dominique Januel, Noomane Bouazi. Clozapine-induced cholinergic urticaria: a case report. Therapeutic advances in psychopharmacology. vol 14. 2024-05-16. PMID:38745850. |
we present the first reported case of cholinergic urticaria induced by clozapine, in a 25-year-old male with treatment-resistant schizophrenia. |
2024-05-16 |
2024-05-27 |
Not clear |
| Florine M Wiss, Samuel S Allemann, Henriette E Meyer Zu Schwabedissen, Céline K Stäuble, Thorsten Mikoteit, Markus L Lamper. Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction. Frontiers in psychiatry. vol 15. 2024-05-14. PMID:38742124. |
a 36-year-old male patient with catatonic schizophrenia was treated with clozapine. |
2024-05-14 |
2024-05-27 |
Not clear |
| Kyle Hewitt, Xu-Feng Huan. Comment on "Impact of clozapine on the expression of miR-675-3p in plasma exosomes derived from patients with schizophrenia". The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2024-05-02. PMID:38693660. |
comment on "impact of clozapine on the expression of mir-675-3p in plasma exosomes derived from patients with schizophrenia". |
2024-05-02 |
2024-05-04 |
Not clear |
| Brooke Gessner, Michelle Carter, Kiana Rahnama, Alberto Almeida, Colleen Borralho, Tamara Mihic, Joan C Y Ng, Joseph H Puyat, Angela Russolillo, Katelyn C Halpap. Clozapine clinical toolkit optimizes inpatient clozapine monitoring. The mental health clinician. vol 14. issue 2. 2024-05-02. PMID:38694883. |
clozapine is the most effective antipsychotic in the management of treatment-resistant schizophrenia; however, its use is challenging due to the risk of severe adverse effects. |
2024-05-02 |
2024-05-04 |
Not clear |
| Yun Tien, Xi-Yu Wang, Shang-Chien Huang, Hsiang-Ping Huan. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study. The Journal of clinical psychiatry. vol 85. issue 2. 2024-05-02. PMID:38696112. |
beneficial effects of concomitant long-acting injectable antipsychotics on time to rehospitalization in patients with treatment-resistant schizophrenia receiving clozapine: a retrospective cohort study. |
2024-05-02 |
2024-05-04 |
Not clear |
| Jose M Rubio, John M Kane, Antti Tanskanen, Jari Tiihonen, Heidi Taipal. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland. The lancet. Psychiatry. 2024-05-02. PMID:38697177. |
agranulocytosis is a life-threatening side-effect of clozapine, the only approved drug for treatment-resistant schizophrenia. |
2024-05-02 |
2024-05-05 |
Not clear |
| Ofer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, Andrea Fagiolini, Oliver D Howes, Niko Seppälä, Christoph U Correl. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 84. 2024-04-24. PMID:38657339. |
overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice. |
2024-04-24 |
2024-04-28 |
Not clear |
| Ofer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, Andrea Fagiolini, Oliver D Howes, Niko Seppälä, Christoph U Correl. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 84. 2024-04-24. PMID:38657339. |
clozapine is the only approved antipsychotic for treatment-resistant schizophrenia (trs). |
2024-04-24 |
2024-04-28 |
Not clear |